UBS Group Reiterates “$136.00” Price Target for Icon (ICLR)

UBS Group set a $136.00 price objective on Icon (NASDAQ:ICLR) in a research report report published on Saturday morning, www.stocktargetadvisor.com reports. The firm currently has a sell rating on the medical research company’s stock.

A number of other equities research analysts have also recently weighed in on the company. BidaskClub upgraded Icon from a hold rating to a buy rating in a research note on Wednesday, September 5th. Zacks Investment Research upgraded Icon from a hold rating to a buy rating and set a $163.00 price objective for the company in a research note on Thursday, August 9th. Robert W. Baird upped their price objective on Icon from $154.00 to $157.00 and gave the stock an outperform rating in a research note on Tuesday, September 11th. Mizuho set a $146.00 price objective on Icon and gave the stock a hold rating in a research note on Monday, August 6th. Finally, KeyCorp upped their price objective on Icon from $152.00 to $157.00 and gave the stock an overweight rating in a research note on Tuesday, September 11th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $148.00.

Shares of NASDAQ ICLR opened at $134.81 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.10 and a quick ratio of 2.10. The firm has a market cap of $7.49 billion, a P/E ratio of 25.04, a P/E/G ratio of 1.98 and a beta of 0.31. Icon has a 1-year low of $101.22 and a 1-year high of $155.33.



Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, October 24th. The medical research company reported $1.54 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.54. The firm had revenue of $655.02 million during the quarter, compared to analysts’ expectations of $654.66 million. Icon had a return on equity of 26.75% and a net margin of 12.88%. As a group, equities analysts forecast that Icon will post 6.08 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the business. Marietta Investment Partners LLC raised its stake in Icon by 18.3% in the second quarter. Marietta Investment Partners LLC now owns 2,472 shares of the medical research company’s stock valued at $328,000 after buying an additional 382 shares during the last quarter. Fisher Asset Management LLC raised its stake in Icon by 1.9% in the second quarter. Fisher Asset Management LLC now owns 21,316 shares of the medical research company’s stock valued at $2,825,000 after buying an additional 400 shares during the last quarter. Cambiar Investors LLC raised its stake in Icon by 9.9% in the second quarter. Cambiar Investors LLC now owns 4,498 shares of the medical research company’s stock valued at $596,000 after buying an additional 405 shares during the last quarter. CIBC Private Wealth Group LLC raised its stake in Icon by 0.5% in the second quarter. CIBC Private Wealth Group LLC now owns 80,342 shares of the medical research company’s stock valued at $10,648,000 after buying an additional 405 shares during the last quarter. Finally, BB&T Corp raised its stake in Icon by 11.5% in the third quarter. BB&T Corp now owns 4,116 shares of the medical research company’s stock valued at $632,000 after buying an additional 425 shares during the last quarter. Institutional investors own 87.38% of the company’s stock.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

See Also: Stock Symbols Definition, Examples, Lookup

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply